Eledoisin
From PeptidePlaza, the free peptide reference · Entry #1034 · Nootropic · Sources fetched 2026-09-10 · Editorial standards
Eledoisin (also known as Eledone peptide, Eledoisina, Eledoisine, Eledoisinum) is a nootropic research peptide. Eledoisin is a research peptide and a member of the tachykinin peptide family, currently in Phase 2 development.
Eledoisin is a naturally occurring undecapeptide originally isolated from the posterior salivary glands of the octopus Eledone moschata. It belongs to the tachykinin family of peptides, which are characterized by a common C-terminal sequence. Eledoisin is recognized for its hypotensive properties and its role in various physiological processes. Research into eledoisin has explored its synthetic analogues and its involvement in areas such as thirst regulation and histamine secretion. It is currently in Phase 2 of clinical development.
1 Chemical and physical properties
| CAS number | 69-25-0 |
|---|---|
| Molar mass | 1188.4 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
1.1 Amino acid sequence
Pyr-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2
2 Research studies (8)
- The tachykinin peptide family
Pharmacological reviews (2002) · Review - Hypotensive peptides: bradykinin, kallidin, and eledoisin
Advances in pharmacology (1966) · Review - Neuropeptides and thirst
Progress in neuro-psychopharmacology & biological psychiatry (1983) - Synthetic peptides related to eledoisin
Experientia (1964) - Induction of histamine secretion by polycations
Biochimica et biophysica acta (1980) - Brain neuropeptides: actions on central cardiovascular control mechanisms
Brain research. Brain research reviews (1989) · Review - Short-term Efficacy and Safety of Biological Tear Substitutes and Topical Secretagogues for Dry Eye Disease: A Systematic Review and Network Meta-analysis
Cornea (2022) · Systematic Review - Control of vascular permeability and vascular smooth muscle in the respiratory tract by multiple neuropeptides
Acta oto-laryngologica. Supplementum (1989) · Review
3 Safety and risk profile
3.1 Regulatory status
Eledoisin is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
4 Frequently asked questions
- What is Eledoisin?
- Eledoisin is a naturally occurring undecapeptide, meaning it is a peptide composed of eleven amino acid residues. It was first identified in the octopus Eledone moschata and is classified as a member of the tachykinin peptide family.
- What is Eledoisin studied for?
- Eledoisin is studied for its hypotensive effects, meaning its ability to lower blood pressure. Research also investigates its role in neuropeptide systems related to thirst and its capacity to induce histamine secretion. Studies have also focused on developing synthetic peptides related to eledoisin.
- What class of compound is Eledoisin?
- Eledoisin is a peptide, specifically an undecapeptide. It is also categorized as a tachykinin, which is a family of neuropeptides sharing a common C-terminal sequence and various biological activities.
- Is Eledoisin FDA approved?
- Eledoisin is not yet FDA approved. It is currently in Phase 2 of clinical development, indicating that it is undergoing further testing to evaluate its efficacy and safety in humans.
5 References
- Eledoisin — compound summary PubChem. View source
- Eledoisin — molecule record ChEMBL. View source
- Eledoisin — published literature (564 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Eledoisin.
Also nootropic
Substance P, also known as Neurokinin P, is an endogenous human peptide and a member of the tachykinin family.
Also nootropic
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also nootropic
A nine-amino-acid neuropeptide hormone best known for childbirth and lactation, now studied extensively for social bonding, stress regulation, wound healing, and metabolic effects via intranasal delivery.
Also nootropic
A cyclic heptapeptide melanocortin receptor agonist and active metabolite of Melanotan II. Unlike peripheral vasodilators, PT-141 acts centrally via the CNS to modulate arousal and food intake pathways.
Also nootropic
A potent cyclic analog of α-MSH that activates melanocortin receptors broadly. Studied for UV-independent melanogenesis, appetite suppression, and as the parent compound of PT-141 (Bremelanotide).
Also nootropic
Eptifibatide is an integrin alpha-IIb/beta-3 inhibitor used to decrease the rate of death or myocardial infarction in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention.